ALK and non-small cell lung carcinoma: Different from their study, we conducted a larger respective cohort as well as included more important variables for analysis, such EGFR and ALK mutation status, ECOG‐performance status, therapeutic regiment, and organ metastasis parameters, which have been verified to exert influence on the clinical outcome of the NSCLC patients.